Coriolis Pharma

Coriolis Pharma is a globally operating and science-driven contract research and development organization (CRDO) in the pharmaceutical industry. Founded in 2008 and based in Germany, the company specializes in supporting drug product development of biopharmaceuticals, including gene and cell therapies, and vaccines from early development to commercialization. Coriolis Pharma's services encompass formulation development, lyophilization technologies, and analytics (GMP and non-GMP) for a diverse range of products. With a focus on proteins, peptides, nucleic acids, gene- and cell therapy products, vaccines, and virus(-like) particles up to biosafety level S2, Coriolis Pharma has positioned itself as a leader in providing tailored solutions for its clients. The company's interdisciplinary team of highly skilled scientists and an expert scientific advisory board enables it to offer cutting-edge services. Although there is no publicly available information on last investment and last investment investors at this time, Coriolis Pharma continues to thrive as a privately held and independent company, emphasizing its commitment to delivering high-quality services and solutions to the biopharmaceutical industry.